This article was initially published in the 11/19/26 edition of our Concussion Update newsletter; please consider subscribing.
A recent article in The New York Times discusses several novel treatments that may reduce the risk of CTE and, more broadly, may reduce neuroinflammation and neurodegeneration due to repeated brain trauma, whether it's from contact sports, Coast Guard high-speed boats, or intimate partner violence. Author Lynne Peeples discusses near-infrared light (photobiomodulation), gut microbiome interventions, vagus nerve stimulation, psychedelic therapy, and pharmaceutical medications. At Concussion Alliance, we’ve been writing about research on these potential treatments for years, and in this synopsis, we’ll provide an overview of the treatments, along with links to more information.
Photobiomodulation (near-infrared light therapy)
Peeples first discusses near-infrared light, also called photobiomodulation (PBM), noting that "Emerging science suggests that the [photobiomodulation] devices may help the brain be more resilient to damage." We wrote about this new research in our article, Light Therapy Promotes Neurological Resilience in College Football Players. Peeples also refers to a small study that found PBM "improved markers of early recovery for patients" with moderate TBI treated within one week of injury; read our blog post for more information. While very limited, there are a few small studies and a case study indicating PBM may help some people with persisting symptoms after concussion. To learn more, see our Light Therapy/Photobiomodulation resource, which includes how to access the devices. We also recommend The Atlantic’s article on PBM.
Psychedelics
The next topic Peeples covers is psychedelics, featuring former 2X Stanley Cup winner Daniel Carcillo, who found that psilocybin therapy relieved his symptoms that were "associated with CTE." See our resources on psychedelics and psilocybin as potential interventions, and read our article about Carcillo's licensed psilocybin service center in Portland, Oregon.
Microbiome interventions
Peeples discusses the microbiome, starting with a small study that "linked mild, non-concussive blows to the head during football with changes in the microbiome." Read our blog post to learn more about this study. A trial with findings "currently under review" suggests the microbiome might dictate recovery or be a target for interventions, according to Lisa Brenner, the trial investigator and director of the VA Brain Health Coordinating Center at the University of Colorado Anschutz. We highly recommend Dr. Brenner's webinar, The Gut-Brain Connection: Microbiome and Mental Health in Military Populations, which we highlighted in our Veterans Day Special Edition Newsletter.
Photobiomodulation and vagal nerve stimulation for the microbiome
These treatments may overlap: photobiomodulation and vagus nerve stimulation may influence the microbiome. Authors of a recent review article write, "The ability of PBM to influence the microbiome (if proven to be applicable to humans) will allow an additional therapeutic route to target multiple diseases." Peeples writes that vagus nerve stimulation may also benefit the microbiome. See our articles on vagus nerve stimulation. Our Photobiomodulation resource includes information on a PBM device that provides light therapy to the head and abdomen, and another device that provides transcranial PBM plus vagal nerve stimulation.
Pharmaceutical medications
Finally, The New York Times article discusses currently available pharmaceutical medications being studied for potential interventions. For example, Baricitinib, a "high-potency anti-inflammatory medication," is currently in a clinical trial to see if it "reduces depressive and cognitive symptoms in patients with depression who have played at least 11 years of organized tackle football." See Being Patient's explanation of the study. We've written about Laurel Schmidt's personal experiment with GLP-1s as a potential intervention (here and here); she announced a partnership with the Brain Inflammation Collective to create a case study. We have also written about Oxeia Biopharmaceuticals' research intoOXE103.
